Inovelon(R) a New Treatment for Lennox-Gastaut Syndrome Reduces Drop Attacks by Over 40%
London (ots/PRNewswire) - - First EMEA Licensed Treatment Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, Chairman and CEO Yutaka Tsuchiya) today announced publication of the results of a major study of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in ...